A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome

Sponsor
Alnylam Pharmaceuticals
Study ID
NCT03303313
Phase
PHASE2
Status
Withdrawn

Conditions

  • Atypical Hemolytic Uremic Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cemdisiran — DRUG
    Subcutaneous (sc) injection of Cemdisiran

Study Details

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Cemdisiran in patients with aHUS.

Key Dates

Start date
Sep 19, 2017
Status verified
Sep 2018
Primary completion
Sep 12, 2018
Completion
Sep 12, 2018

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cemdisiran

Primary Outcome Measure

The effect of Cemdisiran on platelet count [ Time Frame: Week 32 ]

Related Studies